FindTrial
Sign In

Reldesemtiv

DRUG5 trials

Sponsors

Astellas Pharma Global Development, Inc., Cytokinetics

Conditions

Amyotrophic Lateral SclerosisChronic Obstructive Pulmonary Disease (COPD)Mobility Limitation

Phase 1

A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
TerminatedNCT03065959
Astellas Pharma Global Development, Inc.Mobility Limitation
Start: 2017-06-28End: 2018-10-10Updated: 2024-10-31

Phase 2

A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
CompletedNCT02662582
Astellas Pharma Global Development, Inc.Chronic Obstructive Pulmonary Disease (COPD)
Start: 2016-06-30End: 2018-06-08Updated: 2024-11-14
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
CompletedNCT03160898
CytokineticsAmyotrophic Lateral Sclerosis
Start: 2017-07-24End: 2019-03-07Updated: 2020-09-11

Phase 3

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
TerminatedNCT04944784
CytokineticsAmyotrophic Lateral Sclerosis
Start: 2021-08-16End: 2023-07-18Updated: 2024-12-05
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
TerminatedNCT05442775
CytokineticsAmyotrophic Lateral Sclerosis
Start: 2022-08-04End: 2023-06-07Updated: 2024-08-13

Related Papers

The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS.
2026-01-19
Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2025-06-27
Reldesemtiv in Amyotrophic Lateral Sclerosis
JAMA Neurology2025-03-244 citations
Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial.
2023-08-29
COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2023-05-3014 citations
Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving <i>reldesemtiv</i> or placebo in FORTITUDE-ALS
Journal of Medical Economics2023-03-173 citations
MiToS and King's staging as clinical outcome measures in ALS: a retrospective analysis of the FORTITUDE-ALS trial.
2022-12-125 citations
Prescription and acceptance of durable medical equipment in FORTITUDE-ALS, a study of <i>reldesemtiv</i> in ALS: post hoc analyses of a randomized, double-blind, placebo-controlled clinical trial
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2021-07-053 citations
A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of <i>Reldesemtiv</i> In Patients With ALS
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2020-09-2455 citations
A phase III trial of <i>tirasemtiv</i> as a potential treatment for amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration2019-05-1344 citations